CompletedPhase 1NCT01871675
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
Studying T-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SCRI Development Innovations, LLC
- Principal Investigator
- Ian Flinn, M.D.SCRI
- Intervention
- IPI-145(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2016
Study locations (4)
- The Colorado Blood Cancer Institute, Denver, Colorado, United States
- Florida Cancer Specialists, Sarasota, Florida, United States
- Oklahoma University, Oklahoma City, Oklahoma, United States
- Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Collaborators
Infinity Pharmaceuticals, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01871675 on ClinicalTrials.govOther trials for T-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05989204TmCD19-IL18 in CD19+ CancersUniversity of Pennsylvania
- ACTIVE NOT RECRUITINGPHASE1NCT05377827Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesWashington University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT04440436Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) PatientsBeijing Immunochina Medical Science & Technology Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE1NCT03434769AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaBenjamin Tomlinson
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02690545Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHLUNC Lineberger Comprehensive Cancer Center